⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13832600 | 1.00 | — | — | |
| SCHEMBL13738542 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL13738360 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL13740048 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL9135214 | 0.98 | — | — | |
| SCHEMBL3596245 | 0.86 | — | — | |
| SCHEMBL31384945 | 0.86 | — | — | |
| SCHEMBL123988 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL19510774 | 0.85 | HRH3 (0.38) | — | |
| Biphenyl SCHEMBL27602184 | 0.84 | USP30 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551570-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Dong-A ST Co., Ltd. (KR) | 2025-05-14 | — | — | EP | disclosed |
| US-20250122152-A1 | KAT6 Inhibitors | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-17 | — | — | US | disclosed |
| WO-2025068943-A1 | KAT6 INHIBITORS | BEIGENE SWITZERLAND GMBH (CH) | 2025-04-03 | — | — | WO | disclosed |
| US-20250101028-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2025-03-27 | — | — | US | disclosed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| CN-119403798-A | Novel compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | 东亚ST 株式会社 | 2025-02-07 | — | — | CN | disclosed |
| EP-4499639-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BeiGene, Ltd. (KY) | 2025-02-05 | — | — | EP | disclosed |
| CN-118900838-A | Heterocyclic compounds, compositions thereof and methods of treatment thereof | 百济神州有限公司 | 2024-11-05 | — | — | CN | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| WO-2024009215-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-11 | — | — | WO | disclosed |
| WO-2012154676-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154676-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20070191333-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191333-A1 | Antibacterial agents | WARNER LAMBERT COMPANY LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070167447-A1 | Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase | ISTITUTO DI RICERCHE DI BIOLOGIA DI MOLECULOARE P. ANGELETTI SPA (IT) | 2007-07-19 | — | — | US | disclosed |
| EP-1687296-A1 | ANTIBACTERIAL AMINOQUINAZOLIDINEDIONE DERIVATIVES | Warner-Lambert Company LLC (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005049602-A1 | QUINOLONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049605-A1 | ANTIBACTERIAL AMINOQUINAZOLIDINEDIONE DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-02 | — | — | WO | disclosed |
| EP-0556119-B1 | Pyrrolidine derivatives substituted in the 3-position with a saturated or insaturated fatty acid group, process for their preparation and pharmaceuticals with thromboxane A2 inhibiting activity containing them | ADIR (FR) | 1997-05-14 | — | — | EP | disclosed |
| EP-0556119-A1 | Novel pyrrolidine derivatives substituted in the 3-position with a saturated or insaturated fatty acid group, process for their preparation and pharmaceuticals with thromboxane A2 inhibiting activity containing them | ADIR ET COMPAGNIE (FR) | 1993-08-18 | — | — | EP | disclosed |